Data are reported pertaining to the 57 subjects so far found to be heterozygotes for the abnormal factor X (factor X Friuli) coagulation disorder. 41 of these subjects were related to the 11 patients known to be homozygote for the defect. Their average factor X level was 59.7%. The difference between such an average and those found in the homozygote population (10.9%) and in two normal groups (106 and 103%) was statistically significant. The heterozygote usually presents a 1-to 2.5-sec prolongation of the prothrombin time. A significant negative correlation was found to exist between the prothrombin time prolongation in seconds and the percentile factor X level. Factor X in the heterozygote population results to be lower when assayed using human brain or human placenta thromboplastins as compared with a rabbit brain and lung thromboplastin. The cross-over electrophoresis mobility of heterozygote Friuli plasma is identical to that of homozygote Friuli plasma and normal plasma. About one third of the heterozygote patients presented bleeding manifestations.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.